Malin (DUB:MLC) Retained Earnings : €247.70 Mil (As of Dec. 2024)

View and export this data going back to 2014. Start your Free Trial

What is Malin Retained Earnings?

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Malin's retained earnings for the quarter that ended in Dec. 2024 was €247.70 Mil.

Malin's quarterly retained earnings stayed the same from Dec. 2023 (€118.00 Mil) to Jun. 2024 (€118.00 Mil) but then increased from Jun. 2024 (€118.00 Mil) to Dec. 2024 (€247.70 Mil).

Malin's annual retained earnings declined from Dec. 2022 (€257.00 Mil) to Dec. 2023 (€118.00 Mil) but then increased from Dec. 2023 (€118.00 Mil) to Dec. 2024 (€247.70 Mil).

Malin Retained Earnings Historical Data

The historical data trend for Malin's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Malin Retained Earnings Chart

Malin Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Retained Earnings

Get a 7-Day Free Trial

132.60

139.50

257.00

118.00

247.70

Malin Semi-Annual Data
	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Retained Earnings	Get a 7-Day Free Trial															257.00	119.80	118.00	118.00	247.70

Malin Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.

Malin (DUB:MLC) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.

Malin Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Malin Corporation PLC (DUB:MLC) » Definitions » Retained Earnings

Comparable Companies

Traded in Other Exchanges

N/A

Address

50 Richmond Street South, The Lennox Building, Dublin, IRL, D02 FK02

Website

http://www.malinplc.com

Malin Corporation PLC is a life sciences company. Its investee companies are in science and discovery, clinical and commercial sectors. The company's approach is to create shareholder value through the selective long-term application of capital and operational expertise to private, pre-trade sale operating businesses in the life sciences industry. The company derives all of its revenue from its subsidiary. The company focuses on oncology, immunology, and genetic diseases where it believes that life science and healthcare technologies will deliver transformative treatments for patients.

Malin Headlines

No Headlines